PRESTIGE BIOPHARMA LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8,000 KRW | -0.12% |
|
-0.37% | -15.61% |
| Sales 2022 | - | Sales 2023 | 161.84 223K 12.96K | Capitalization | 114B 156,341B 9,094B |
|---|---|---|---|---|---|
| Net income 2022 | -211B -291,052B -16,929B | Net income 2023 | 17.57B 24,183B 1,407B | EV / Sales 2022 | - |
| Net cash position 2022 | 299B 411,590B 23,941B | Net cash position 2023 | 217B 298,746B 17,377B | EV / Sales 2023 | -639,252,890 x |
| P/E ratio 2022 |
-3.02
x | P/E ratio 2023 |
32.3
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.12% | ||
| 1 week | -0.37% | ||
| Current month | -10.01% | ||
| 1 month | -4.65% | ||
| 3 months | -1.96% | ||
| 6 months | -20.24% | ||
| Current year | -15.61% |
1 week
7 950.00
8 440.00
1 month
7 850.009 800.00
Current year
7 850.0010 200.00
1 year
7 850.0014 920.00
3 years
7 020.0040 850.00
5 years
7 020.0054 000.00
10 years
7 020.0054 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
So-Yeon Park
CEO | Chief Executive Officer | 61 | - |
Lai Wat Tay
DFI | Director of Finance/CFO | 68 | - |
Jin Woo Kim
COO | Chief Operating Officer | 60 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lai Wat Tay
DFI | Director of Finance/CFO | 68 | - |
So-Yeon Park
CEO | Chief Executive Officer | 61 | - |
Eui-Kyung Lee
BRD | Director/Board Member | 65 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 8,000 | -0.12% | 18,299 |
| 25/04/24 | 8,010 | -0.62% | 19,303 |
| 24/04/24 | 8,060 | +0.62% | 16,685 |
| 23/04/24 | 8,010 | -0.62% | 64,728 |
| 22/04/24 | 8,060 | +0.37% | 11,901 |
End-of-day quote Korea S.E., April 25, 2024
More quotes
Prestige Biopharma Ltd is a Singapore-based biopharmaceutical company. The Company is focused on the development of biosimilars and antibody drugs as well as vaccines for infectious diseases. Its biosimilar portfolio consists of over 12 pipelines, including HD201 (trastuzumab) in Phase III, HD204 (bevacizumab) in Phase III, and PBP1502 (adalimumab) in Phase I. Its antibody therapeutic portfolio includes PBP1510, PBP1710, IDC001, IDC005, IDC007, IDC008 and others. PBP1510 specifically binds pancreatic adenocarcinoma upregulated factor (PAUF), a protein that drives cancer cells to spread through blood flow and to escape immune recognition and exerts anti-metastasis and immune modulation effects. PBP1710 specifically binds to collagen triple helix repeat containing 1 (CTHRC1), a protein that facilitates cancer cells and exerts anti-metastasis and anti-tumor growth effects. IDC001 is designed to treat cancers that express high level of PAUF and CTHRC1.
Sector
Pharmaceuticals
Calendar
16/09/2024
- Q4 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -15.61% | 69.86M | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -16.09% | 15.36B | |
| -9.14% | 11.95B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| +5.24% | 8.71B |
- Stock Market
- Equities
- A950210 Stock
